Yolanda D Tseng1, Yu-Hui Chen2, Paul J Catalano3, Andrea Ng4. 1. Department of Radiation Oncology, University of Washington, Seattle, Washington. Electronic address: ydt2@uw.edu. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. 4. Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
PURPOSE: To evaluate the response rate (RR) and time to local recurrence (TTLR) among patients who received salvage radiation therapy for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) and investigate whether RR and TTLR differed according to disease characteristics. METHODS AND MATERIALS: A retrospective review was performed for all patients who completed a course of salvage radiation therapy between January 2001 and May 2011 at Brigham and Women's Hospital/Dana-Farber Cancer Institute. Separate analyses were conducted for patients treated with palliative and curative intent. Predictors of RR for each subgroup were assessed using a generalized estimating equation model. For patients treated with curative intent, local control (LC) and progression-free survival were estimated with the Kaplan-Meier method; predictors for TTLR were evaluated using a Cox proportional hazards regression model. RESULTS: Salvage radiation therapy was used to treat 110 patients to 121 sites (76 curative, 45 palliative). Salvage radiation therapy was given as part of consolidation in 18% of patients treated with curative intent. Median dose was 37.8 Gy, with 58% and 36% of curative and palliative patients, respectively, receiving 39.6 Gy or higher. The RR was high (86% curative, 84% palliative). With a median follow-up of 4.8 years among living patients, 5-year LC and progression-free survival for curative patients were 66% and 34%, respectively. Refractory disease (hazard ratio 3.3; P=.024) and lack of response to initial chemotherapy (hazard ratio 4.3; P=.007) but not dose (P=.93) were associated with shorter TTLR. Despite doses of 39.6 Gy or higher, 2-year LC was only 61% for definitive patients with refractory disease or disease that did not respond to initial chemotherapy. CONCLUSIONS: Relapsed or refractory aggressive NHL is responsive to salvage radiation therapy, and durable LC can be achieved in some cases. However, refractory disease is associated with a shorter TTLR, suggesting that radiation dose escalation, addition of radiosensitizers, or a combination of both may be indicated in these patients.
PURPOSE: To evaluate the response rate (RR) and time to local recurrence (TTLR) among patients who received salvage radiation therapy for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) and investigate whether RR and TTLR differed according to disease characteristics. METHODS AND MATERIALS: A retrospective review was performed for all patients who completed a course of salvage radiation therapy between January 2001 and May 2011 at Brigham and Women's Hospital/Dana-Farber Cancer Institute. Separate analyses were conducted for patients treated with palliative and curative intent. Predictors of RR for each subgroup were assessed using a generalized estimating equation model. For patients treated with curative intent, local control (LC) and progression-free survival were estimated with the Kaplan-Meier method; predictors for TTLR were evaluated using a Cox proportional hazards regression model. RESULTS: Salvage radiation therapy was used to treat 110 patients to 121 sites (76 curative, 45 palliative). Salvage radiation therapy was given as part of consolidation in 18% of patients treated with curative intent. Median dose was 37.8 Gy, with 58% and 36% of curative and palliative patients, respectively, receiving 39.6 Gy or higher. The RR was high (86% curative, 84% palliative). With a median follow-up of 4.8 years among living patients, 5-year LC and progression-free survival for curative patients were 66% and 34%, respectively. Refractory disease (hazard ratio 3.3; P=.024) and lack of response to initial chemotherapy (hazard ratio 4.3; P=.007) but not dose (P=.93) were associated with shorter TTLR. Despite doses of 39.6 Gy or higher, 2-year LC was only 61% for definitive patients with refractory disease or disease that did not respond to initial chemotherapy. CONCLUSIONS: Relapsed or refractory aggressive NHL is responsive to salvage radiation therapy, and durable LC can be achieved in some cases. However, refractory disease is associated with a shorter TTLR, suggesting that radiation dose escalation, addition of radiosensitizers, or a combination of both may be indicated in these patients.
Authors: Mary-Elizabeth M Percival; Ryan C Lynch; Anna B Halpern; Mazyar Shadman; Ryan D Cassaday; Chaitra Ujjani; Andrei Shustov; Yolanda D Tseng; Catherine Liu; Steven Pergam; Edward N Libby; Bart L Scott; Stephen D Smith; Damian J Green; Ajay K Gopal; Andrew J Cowan Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Qian Qin; Xinyu Nan; Tara Miller; Ronald Fisher; Bin Teh; Shruti Pandita; Andrew M Farach; Sai Ravi Pingali; Raj K Pandita; E Brian Butler; Tej K Pandita; Swaminathan P Iyer Journal: Radiat Res Date: 2018-06-27 Impact factor: 2.841
Authors: Chelsea C Pinnix; Jillian R Gunther; Bouthaina S Dabaja; Paolo Strati; Penny Fang; Misha C Hawkins; Sherry Adkins; Jason Westin; Sairah Ahmed; Luis Fayad; Hun Ju Lee; Ranjit Nair; Raphael E Steiner; Swaminathan P Iyer; M Alma Rodriguez; Michael Wang; Christopher Flowers; Sattva S Neelapu; Loretta J Nastoupil Journal: Blood Adv Date: 2020-07-14